Navigation Links
NewCardio to Sponsor and Present at 4th Annual Cardiac Safety Assessment Summit
Date:12/22/2009

SANTA CLARA, Calif., Dec. 22 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Dr. Ihor Gussak, Ph.D., F.A.C.C., NewCardio's Vice President and Chief Medical Officer, will join a distinguished roster of speakers, moderators and panelists at the Center for Business Intelligence (CBI) 4th Annual Cardiac Safety Assessment Summit. The Conference is scheduled for January 12 and 13, 2010, at the Madison A Loews Hotel in Washington, DC. NewCardio is one of the sponsors of the conference, and Dr. Gussak will participate in a panel discussion on the Clinical Validation of Automated ECG Reading Methods.

Dr. Gussak will join Moderator Philip Sager, M.D., Vice President, Clinical Research, Gilead Sciences, Inc. Other participants on the panel include Dr. Borje Darpo, Pharmaceutical Consultant, Dr., Nenad Sarapa, Head of Clinical Pharmacology-Oncology, Hoffmann-La Roche, Inc., and Dr. J. Rick Turner, Senior Director, Cardiovascular Safety, Quintiles ECG Services, on the Clinical Validation of Automated ECG Reading Methods panel to examine the comparison between human readers and automated ECG measurements. The panel will also discuss the evolving approaches to automated QT analyses and their impact on the performance of TQT studies.

Dr. Gussak commented, "I am excited to discuss NewCardio's platform technology and QTinno(TM), our automated cardiac safety solution, at this important and prestigious conference. NewCardio remains committed to improving accuracy and bringing enhanced value to cardiac safety in pharmaceutical development. I am eager to share our latest clinical validation results from blinded studies using QTinno(TM). These results continue to demonstrate that QTinno provides highly accurate results with reduced intrinsic variability and narrower confidence intervals, relative to currently used manual or semi-automated methods."

CBI Research, Inc. is a subsidiary of Advanstar Communications Inc, and dedicated to developing market-driven, unbiased conferences in the fields of pharmaceuticals and biotech, medical devices, risk and insurance and managed care markets. CBI Research, Inc. creates conferences and summits that serve senior executives and government officials by providing a unique platform for highly focused content and presentation. The Cardiac Safety Assessment Summit will provide sessions to discuss how to measure and manage cardiac safety issues such as Arrhythmia, Ischemic Heart Disease, Cardiomyopothy and drugs that effect heart rate and blood pressure. Cardiac safety considerations in Cardiovascular, Oncology, HIV and Diabetes drugs are also explored. More information is available at http://www.cbinet.com/show_conference.cfm?confCode=PC10102&field=summary online.

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0


    Investor Contact:
    Hayden IR
    Jeff Stanlis, Partner and VP of Communications
    (602) 476-1821
    jeff@haydenir.com

SOURCE NewCardio, Inc.


'/>"/>
SOURCE NewCardio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. NewCardio Announces Master Services Agreement With Dedicated Phase I
2. NewCardio Leadership to Present Two Abstracts at ISCE Conference
3. Vincent W. Renz Joins NewCardio as President
4. NewCardio Announces Positive Results From Third Clinical Validation Study
5. Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation
6. AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float
7. Stipkala LLC to Sponsor SEBIO 2009
8. Boston Scientific Announces Sponsorship of World Diabetes Day Campaign 2009
9. Stipkala LLC to Sponsor Texas Life Science Conference November 12-13, 2009
10. EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimers Disease Patient
11. FDA Warning Letters Caused Dramatic Decline in Sponsored Link Exposures, According to comScore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... PUNE, India , May 25, 2016 ... "Medical Animation Market by Type (3D, 2D, 4D), by ... Patient Education), by End User (Medical Device Manufacturers, Hospitals/ ... report studies the global Medical Animation Market for the ... expected to reach USD 301.3 Million by 2021 from ...
(Date:5/25/2016)...  According to Kalorama Information, the world market ... Though these are challenging times in the market, ... for companies that remain optimistic and seek innovation.  ... prospects medical device companies spend a higher percentage ... than do companies in other industries.  Also, in ...
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... ... "Color Grading media can be time consuming but with FCPX LUT Night ... Austin - CEO of Pixel Film Studios. , With the FCPX LUT Night ... to their footage. A LUT is a Lookup Table that contains a mathematical formula ...
(Date:5/27/2016)... CA (PRWEB) , ... May 27, 2016 , ... More ... Health, so it is not surprising that bariatric surgery has received increased attention in ... Journal explains. Of course, when it comes to weight loss, most people are familiar ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and ... to shed lights on the variety of topics detailing why we appreciate nurses in ... why this career has gone from being in a major recession to one of ...
(Date:5/27/2016)... ... 27, 2016 , ... In response to meager public awareness, ... of the plight of aphasia. In collaboration with the American Aphasia Association, a ... The link between stroke and aphasia is relatively unknown, but through collaboration with ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year ... complementary medicine. Allison Outerbridge is this year’s Life University winner of ... at the university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last ...
Breaking Medicine News(10 mins):